A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atropine (Primary)
Indications Myopia
Focus Registrational; Therapeutic Use
Acronyms Mini-CHAMP
Sponsors Zhaoke Guangzhou Ophthalmology Pharmaceutical

Most Recent Events

29 Jan 2025 Primary endpoint has been met. (Cycloplegic Autorefraction(low)), according to Vyluma media release.
29 Jan 2025 According to Vyluma media release, the National Medical Products Administration (NMPA) of China has accepted the drug application.
16 Jan 2025 Planned End Date changed from 1 Aug 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight